1Lopez-Arrieta, Birks J. Nimodipine for primary degenerative,mixed and vascular dementia[DB/OL]. The Cochrane Database of Systematic Reviews. 2003, Issue 3.
2Doody RS, Stevens JC, Beck C, et al. Practice parameter:management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology[J]. Neurology, 2001,56:1154-1166 .
3De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies cardiovascular disease prevention in clinical practice(constituted by representatives of eight societies and by invited experts) [J]. Ettr J Cardiovase Prey and Rehabil, 2003,10(4) : S1-S10.
4Future Directions for Dementia Care and Support in NSW 2001-2006, Department of Ageing, Disability and Home Care.The Dementia Epidemic: Economic Impact and Positive Solutions for Australia[C]. Australia, March, 2003.
5Pantoni L, Rossi R, Inzitari D , et al. Efficacy and safety of nimodipine in subcortical vascular dementia: asubgroup analysis of the Scandinavian Multi-Infarct Dementia Trial [J].Journal of the Neurological Sciences, 2000,175:124-134.
6Sze KH, Sim TC, Wong E, et al. Effect of Nimodipine on memory after cerebral infarction [J]. Acta Neurel Scand, 1998,97 : 386-392.
